Summit says bispecific misses overall survival in closely-watched lung cancer study Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory future unclear after mixed EGFR+ NSCLC results.

⚡ BREAKING: Summit says PD-1xVEGF bispecific ivonsecimab misses overall survival in closely-watched lung cancer study $SMMT
endpts.com/summit-says-...

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes Eli Lilly reported the first Phase 3 data for its oral GLP-1 orforglipron Thursday morning, saying the drug succeeded in a type 2 diabetes trial. The drug hit the primary ...

Lilly's oral GLP-1 looks good in diabetes, but the real test is the upcoming obesity readout. Nice piece from @maxgelman.bsky.social here:

In a blow to its obesity pipeline, Pfizer drops oral drug after liver injury case Pfizer discontinues obesity pill danuglipron after potential drug-induced liver injury in trial patient; company has GIP receptor antagonist PF-07976016 in Phase 2a testing.

Pfizer has dropped its obesity pill danuglipron:

Screenshot of the Financial Times's health news page, featuring an article that reads: "Is your bed wearing a skirt? The valance is the solution to all your storage problems".

I love the FT's health section but every once in a while it posts a bit of a head-scratcher.

Zealand partners with Roche on its amylin analog in a deal worth $5.3B Zealand Pharma partners with Roche on obesity drug petrelintide in $5.3B deal. Roche pays $1.4B upfront, plans combo studies with CT-388. Companies to split revenues in US/Europe.

Zealand finally got its petre partner - and it's *drumroll* Roche!

$1.4B upfront, $5.3 in biobucks. Not bad.

Arvinas, Pfizer’s PROTAC data fall short of expectations in breast cancer Arvinas/Pfizer's vepdegestrant shows efficacy in mutated breast cancer patients but not in broader population, failing to outperform similar drugs, Phase 3 VERITAC-2 trial show

The hotly-awaited vepdegestrant data are in from Arvinas and Pfizer, and they're not as good as hoped. My take for @endpts.com

The Endpoints 100: The biotech industry braces for Trump 2.0 A survey of 77 biotech executives reveals concerns about FDA changes following Donald Trump's reelection. Martin Makary's nomination as FDA chief has eased some worries, while Robert F. Kennedy Jr.'s ...

There's a huge amount of useful data and raw sentiment in the latest E100 survey that John Carroll, Endpoints Editor and Founder, conducted for Endpoints readers. We heard from 75 top leaders in biopharma on China, Trump the FDA + more: endpts.com/the-endpoint...